Patents Examined by Lawrence Crane
  • Patent number: 6911435
    Abstract: Adenosine and active agent which interact with the adenosine system are used to treat conditions of weakened, immune system, as an anti-cancer therapy and for improving the therapeutic index of a variety of therapeutic drugs.
    Type: Grant
    Filed: July 10, 1998
    Date of Patent: June 28, 2005
    Assignee: Can-Fite Biopharma Ltd.
    Inventors: Ilan Cohn, Pnina Fishman
  • Patent number: 6822089
    Abstract: Methods for preparing deoxynucleosides from their corresponding ribonucleosides by forming 3-tert-butylphenoxythiocarbonylderivatives of the ribonucleosides and subsequently effecting radical deoxygenation reactions at the carbon atoms to be deoxygenated.
    Type: Grant
    Filed: March 29, 2000
    Date of Patent: November 23, 2004
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Yogesh S. Sanghvi, Zhiqiang Guo
  • Patent number: 6797521
    Abstract: The present invention relates to fluorescent cobalamins and uses of these compounds. More particularly, this invention relates to fluorescent cobalamins that comprise a fluorescent, phosphorescent, luminescent or light-producing compound covalently linked to cobalamin. These fluorescent cobalamins can be used to as diagnostic and prognostic markers (a) to distinguish cancer cells and tissues from healthy cells and tissues, including identifying lymph nodes containing cancer cells, and (b) to determine if an individual will respond positively to chemotherapy using cobalamin-therapeutic bioconjugates.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: September 28, 2004
    Assignee: University of Utah Research Foundation
    Inventors: Charles B. Grissom, Frederick G. West, James McGreevy, Joel S. Bentz, Michelle J. Cannon
  • Patent number: 6765089
    Abstract: This invention relates to methods for synthesis of organic compounds, and in particular to compounds useful as protecting and linking groups for use in the synthesis of peptides, oligosaccharides, glycopeptides and glycolipids. The invention provides protecting and linking groups that are useful in both solid phase and solution synthesis, and are particularly applicable to combinatorial synthesis.
    Type: Grant
    Filed: March 20, 2000
    Date of Patent: July 20, 2004
    Assignee: Alchemia Pty Ltd
    Inventors: Istvan Toth, Gyula Dekany, Barry Kellam
  • Patent number: 6706691
    Abstract: The present invention is directed to immunosupportive, drug sparing diets and methods of using these diets. The compositions and methods disclosed herein increase the bioavailability of pharmaceutical compositions metabolized by the gut P450 isozymes.
    Type: Grant
    Filed: July 15, 1998
    Date of Patent: March 16, 2004
    Assignees: Board of Regents, The University of Texas System, Rice University
    Inventors: Charles T. Van Buren, Fred Rudolph
  • Patent number: 6680302
    Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.
    Type: Grant
    Filed: December 27, 2001
    Date of Patent: January 20, 2004
    Assignee: Hospital Sainte-Justine
    Inventors: Ernest G. Seidman, Yves Théorêt
  • Patent number: 6602990
    Abstract: A process for the production of a porous cross-linked polysaccharide gel and a gel obtainable by the following steps: a) preparing a solution or dispersion of the polysaccharide; b) adding a bifunctional cross-linking agent having one active site and one inactive site to the solution or dispersion from step a); c) reacting hydroxylgroups of the polysaccharide with the active site of the cross-linking agent; d) forming a polysaccharide gel; e) activating the inactive site of the cross-linking agent; f) reacting the activated site from step e) with hydroxylgroups of the polysaccharide gel, whereby cross-linking of the gel takes place. The cross-linked polysaccharide gel obtained can further be cross-linked by conventional methods, one or several times.
    Type: Grant
    Filed: May 11, 1999
    Date of Patent: August 5, 2003
    Assignee: Amersham Biosciences AB
    Inventor: Hans Berg
  • Patent number: 6600028
    Abstract: Nucleoside analogues have structure (2) wherein Q is H or a sugar moiety or sugar analogue or a modified sugar or a nucleic backbone or backbone analogue, W is an alkylene or alkenylene chain of 0-5 carbon atoms, any of which may carry a substituent R8, X is O or N or NR12 or CR10, X′ is O or S or N, provided that when X′ is O or S, then X is C, Y is CH or N, R6 is NH2 or SMe or SO2Me or NHNH2, each of R7 and R8 is independently H or F or alkyl or alkenyl or aryl or acyl or a reporter moiety, R12 is independently H or alkyl or alkenyl or aryl or acyl or a reporter moiety, and R10 is H or ═O or F or alkyl or aryl or a reporter moiety.
    Type: Grant
    Filed: February 1, 2000
    Date of Patent: July 29, 2003
    Assignee: Amersham Pharmacia Biotech UK Limited
    Inventors: Daniel Brown, David Loakes, David Williams, Fergal Hill, Shiv Kumar, Satyam Nampalli, Mark McDougall, Alan Hamilton, Clifford Smith, Adrian Christopher Simmonds, William Jonathan Cummins, Patrick Finn
  • Patent number: 6455506
    Abstract: The present invention pertains to D- and L-lyxofuranosyl benzimidazole compounds. In one embodiment, the present invention pertains to D- and L-lyxofuranosyl benzimidazole compounds selected from the group consisting of compounds having a formula selected from the following: wherein R2, R4, R5, R6, and R7 are independently the same or different and independently selected from the group consisting of: —H, —F, —Cl, —Br, —I, —NO2, —N(R8)2, —OR8, —SR12, and —CF3, wherein R8 is independently —H or an alkyl group having 1-6 carbon atoms and wherein R12 is independently —H or a hydrocarbyl group having 1-10 carbon atoms; and, R9, R10 and R11 are independently the same or different and are H or a hydroxyl protecting group; anomeric and optical isomers thereof; and, pharmaceutically acceptable salts and prodrug derivatives thereof.
    Type: Grant
    Filed: July 29, 1998
    Date of Patent: September 24, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: Leroy B. Townsend, John C. Drach